Treatment of epithelial ovarian cancer
L Kuroki, SR Guntupalli - Bmj, 2020 - bmj.com
Ovarian cancer is the third most common gynecologic malignancy worldwide but accounts
for the highest mortality rate among these cancers. A stepwise approach to assessment …
for the highest mortality rate among these cancers. A stepwise approach to assessment …
Ovarian cancer
UA Matulonis, AK Sood, L Fallowfield… - Nature reviews Disease …, 2016 - nature.com
Ovarian cancer is not a single disease and can be subdivided into at least five different
histological subtypes that have different identifiable risk factors, cells of origin, molecular …
histological subtypes that have different identifiable risk factors, cells of origin, molecular …
Personalized cancer vaccine effectively mobilizes antitumor T cell immunity in ovarian cancer
JL Tanyi, S Bobisse, E Ophir, S Tuyaerts… - Science translational …, 2018 - science.org
We conducted a pilot clinical trial testing a personalized vaccine generated by autologous
dendritic cells (DCs) pulsed with oxidized autologous whole-tumor cell lysate (OCDC) …
dendritic cells (DCs) pulsed with oxidized autologous whole-tumor cell lysate (OCDC) …
Homologous recombination deficiency: exploiting the fundamental vulnerability of ovarian cancer
PA Konstantinopoulos, R Ceccaldi, GI Shapiro… - Cancer discovery, 2015 - AACR
Approximately 50% of epithelial ovarian cancers (EOC) exhibit defective DNA repair via
homologous recombination (HR) due to genetic and epigenetic alterations of HR pathway …
homologous recombination (HR) due to genetic and epigenetic alterations of HR pathway …
NCCN guidelines insights: Ovarian cancer, version 1.2019: Featured updates to the NCCN guidelines
DK Armstrong, RD Alvarez, JN Bakkum-Gamez… - Journal of the National …, 2019 - jnccn.org
Epithelial ovarian cancer is the leading cause of death from gynecologic cancer in the
United States, with less than half of patients living> 5 years from diagnosis. A major …
United States, with less than half of patients living> 5 years from diagnosis. A major …
[HTML][HTML] Ovarian cancer
T Arora, S Mullangi, MR Lekkala - 2021 - europepmc.org
Objectives: Describe the epidemiology of ovarian cancer. Review the evaluation of a patient
with suspected ovarian cancer. Summarize the treatment options of ovarian cancer. Outline …
with suspected ovarian cancer. Summarize the treatment options of ovarian cancer. Outline …
Prognostically relevant gene signatures of high-grade serous ovarian carcinoma
RGW Verhaak, P Tamayo, JY Yang… - The Journal of …, 2012 - Am Soc Clin Investig
Because of the high risk of recurrence in high-grade serous ovarian carcinoma (HGS-OvCa),
the development of outcome predictors could be valuable for patient stratification. Using the …
the development of outcome predictors could be valuable for patient stratification. Using the …
Latest research and treatment of advanced-stage epithelial ovarian cancer
RL Coleman, BJ Monk, AK Sood… - Nature reviews Clinical …, 2013 - nature.com
The natural history of ovarian cancer continues to be characterized by late-stage
presentation, metastatic bulky disease burden and stagnant mortality statistics, despite …
presentation, metastatic bulky disease burden and stagnant mortality statistics, despite …
Incorporation of pazopanib in maintenance therapy of ovarian cancer
Purpose Pazopanib is an oral, multikinase inhibitor of vascular endothelial growth factor
receptor (VEGFR)-1/-2/-3, platelet-derived growth factor receptor (PDGFR)-α/-β, and c-Kit …
receptor (VEGFR)-1/-2/-3, platelet-derived growth factor receptor (PDGFR)-α/-β, and c-Kit …
Ovarian cancer
BT Hennessy, RL Coleman, M Markman - The lancet, 2009 - thelancet.com
The standard initial management of epithelial ovarian cancer consists of surgical staging,
operative tumour debulking including total abdominal hysterectomy and bilateral salpingo …
operative tumour debulking including total abdominal hysterectomy and bilateral salpingo …